Clearmind Medicine Inc.
CMND · NASDAQ
7/31/2025 | 4/30/2025 | 1/31/2025 | 10/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $13 | $12 | $12 | $12 |
| Gross Profit | -$13 | -$12 | -$12 | -$12 |
| % Margin | – | – | – | – |
| R&D Expenses | $723 | $452 | $461 | $484 |
| G&A Expenses | $949 | $855 | $1,035 | $1,060 |
| SG&A Expenses | $949 | $855 | $1,035 | $1,091 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$277 | $0 | -$12 | $0 |
| Operating Expenses | $1,395 | $1,307 | $1,484 | $1,575 |
| Operating Income | -$1,408 | -$1,307 | -$1,496 | -$1,586 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $102 | $544 | $464 | $799 |
| Pre-Tax Income | -$1,305 | -$763 | -$1,032 | -$788 |
| Tax Expense | $8 | $21 | $39 | $97 |
| Net Income | -$1,314 | -$784 | -$1,072 | -$885 |
| % Margin | – | – | – | – |
| EPS | -0.34 | -0.21 | -0.35 | -0.3 |
| % Growth | -61.9% | 40% | -16.7% | – |
| EPS Diluted | -0.34 | -0.21 | -0.35 | -0.3 |
| Weighted Avg Shares Out | 5,342 | 5,035 | 4,488 | 4,080 |
| Weighted Avg Shares Out Dil | 5,342 | 5,036 | 4,489 | 4,080 |
| Supplemental Information | – | – | – | – |
| Interest Income | $33 | $42 | $34 | $92 |
| Interest Expense | $9 | $8 | $9 | $36 |
| Depreciation & Amortization | $13 | $12 | $12 | $12 |
| EBITDA | -$1,284 | -$1,295 | -$1,012 | -$1,180 |
| % Margin | – | – | – | – |